晚期黑色素瘤疗效与安全性的系统综述及网络荟萃分析
该研究通过系统文献综述和网络荟萃分析,纳入28项III期随机对照试验共14376例晚期黑色素瘤患者,比较了19种治疗方案的疗效与安全性。结果显示,达拉非尼联合曲美替尼和维莫非尼联合考比替尼在无进展生存期方面最优,但安全性较差;而纳武利尤单抗联合伊匹木单抗、纳武利尤单抗和帕博利珠单抗在总生存期方面更优。
要点
- 达拉非尼联合曲美替尼和维莫非尼联合考比替尼PFS最优但安全性较差。
- 纳武利尤单抗联合伊匹木单抗、纳武利尤单抗和帕博利珠单抗OS更优。
- 网络荟萃分析为晚期黑色素瘤治疗决策提供相对疗效与安全性证据。
核心结论
- 网络荟萃分析识别了晚期黑色素瘤最有效的治疗选择,并提供了各新疗法相对疗效与安全性的见解。
研究设计与样本
- 系统文献综述检索Embase、MEDLINE和Cochrane数据库,时间范围为2010年1月1日至2019年3月11日。
- 纳入28项III期随机对照试验,共涉及14376例患者。
- 采用贝叶斯固定效应网络荟萃分析,以达卡巴嗪为参照治疗,并按RCT设计将达卡巴嗪与替莫唑胺、紫杉醇及紫杉醇联合卡铂合并。
- 仅纳入未接受过新疗法治疗的患者以增加研究人群同质性。
主要发现
- 无进展生存期方面,达拉非尼联合曲美替尼(HR PFS: 0.21)和维莫非尼联合考比替尼(HR PFS: 0.22)为最有利治疗,但两者安全性较差。
- 其他五种治疗紧随其后:达拉非尼(HR PFS: 0.30)、纳武利尤单抗联合伊匹木单抗(HR PFS: 0.34)、维莫非尼(HR PFS: 0.38)、纳武利尤单抗(HR PFS: 0.42)和帕博利珠单抗(HR PFS: 0.46)。
- 总生存期方面,纳武利尤单抗联合伊匹木单抗(HR OS: 0.39)、纳武利尤单抗(HR OS: 0.46)和帕博利珠单抗(HR OS: 0.50)优于达拉非尼联合曲美替尼(HR OS: 0.55)和维莫非尼联合考比替尼(HR OS: 0.57)。
关键数值与推荐
- 共检索到28项III期随机对照试验,涉及14376例患者。
临床怎么用
- 网络荟萃分析结果可为晚期黑色素瘤的循证决策提供信息,并可能支持日常临床实践中治疗和结局的优化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although a myriad of novel treatments entered the treatment paradigm for advanced melanoma, there is lack of head-to-head evidence. We conducted a network meta-analysis (NMA) to estimate each treatment's relative effectiveness and safety. METHODS: A systematic literature review (SLR) was conducted in Embase, MEDLINE and Cochrane to identify all phase III randomised controlled trials (RCTs) with a time frame from January 1, 2010 to March 11, 2019. We retrieved evidence on treatment-related grade III/IV adverse events, progression-free survival (PFS) and overall survival (OS). Evidence was synthesised using a Bayesian fixed-effect NMA. Reference treatment was dacarbazine. In accordance with RCTs, dacarbazine was pooled with temozolomide, paclitaxel and paclitaxel plus carboplatin. To increase homogeneity of the study populations, RCTs were only included if patients were not previously treated with novel treatments. RESULTS: The SLR identified 28 phase III RCTs involving 14,376 patients. Nineteen and seventeen treatments were included in the effectiveness and safety NMA, respectively. For PFS, dabrafenib plus trametinib (hazard ratio [HR] PFS: 0.21) and vemurafenib plus cobimetinib (HR PFS: 0.22) were identified as most favourable treatments. Both had, however, less favourable safety profiles. Five other treatments closely followed (dabrafenib [HR PFS: 0.30], nivolumab plus ipilimumab [HR PFS: 0.34], vemurafenib [HR PFS: 0.38], nivolumab [HR PFS: 0.42] and pembrolizumab [HR PFS: 0.46]). In contrast, for OS, nivolumab plus ipilimumab (HR OS: 0.39), nivolumab (HR OS: 0.46) and pembrolizumab (HR OS: 0.50) were more favourable than dabrafenib plus trametinib (HR OS: 0.55) and vemurafenib plus cobimetinib (HR OS: 0.57). CONCLUSIONS: Our NMA identified the most effective treatment options for advanced melanoma and provided valuable insights into each novel treatment's relative effectiveness and safety. This information may facilitate evidence-based decision-making and may support the optimisation of treatment and outcomes in everyday clinical practice.
引用
- Franken MG, Leeneman B, Gheorghe M, et al. A systematic literature review and network meta-analysis of effectiveness and safety outcomes in advanced melanoma. Eur J Cancer. 2019. PMID: 31670077. doi:10.1016/j.ejca.2019.08.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。